GLS-5700 DNA Vaccine for Prevention of Infection from Zika Virus
GLS-5700 is a synthetic vaccine being developed by Inovio Pharmaceuticals and GeneOne Life Sciences to prevent and treat infections caused by the Zika virus.
Preclinical Contract Research Organisation
Karolinska Science Park,
Fogdevreten 2a,
Stockholm,
171 77 Other,
Sweden
Pronexus Analytical is a preclinical contract research organisation (CRO) offering advanced services in pharmacology of the central nervous system (CNS), neurochemistry and neurophysiology. Pronexus’ core expertise is focused on in vivo techniques for monitoring neurotransmitter release and metabolism, animal models of CNS disorders, PK/PD studies and testing the implantable medical devices and drug delivery systems.
Collectively, we have more than 75 years of research experience in CNS pharmacology, proof-of-concept studies and evaluation of mechanisms of drug actions using microdialysis and related bioanalytical techniques, biosensors and electrophysiological recordings.
The bioanalytical services include high-sensitive HPLC techniques and immunoassays for determination of neurotransmitters and other neuroactive molecules, as well as metabolites and drug levels in the microdialysis samples, plasma, CSF, cell lysates and brain tissue extracts. The bioanalytical laboratory and the animal research facility are GLP-compliant with full regulatory approvals. All services provided by Pronexus Analytical are carried out under strictly professional non-disclosure agreements.
Pronexus Analytical provides determination of biomolecules in microdialysis samples, tissue extracts, plasma, CSF, urine and other body fluids:
GLS-5700 is a synthetic vaccine being developed by Inovio Pharmaceuticals and GeneOne Life Sciences to prevent and treat infections caused by the Zika virus.
Karolinska Science Park
Fogdevreten 2a
Stockholm
171 77
Other
Sweden